You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3981]

  • In development
  • Reference number: GID-TA10912
  • Expected publication date:  10 September 2025
  • Project information
  • Project documents

On this page

  1. Declaration of interests
  2. Draft guidance
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3981

Documents

Documents created during the development process.

Declaration of interests

  • Register of interests (PDF 104 KB)

    Published:
    04 July 2025

Draft guidance

  • Draft guidance

  • Draft guidance (online commenting)

  • Draft guidance (downloadable version) (PDF 236 KB)

    Published:
    29 May 2025
  • Committee papers (PDF 8.68 MB)

    Published:
    29 May 2025
  • Public committee slides (PDF 745 KB)

    Published:
    29 May 2025
  • Equality impact assessment (downloadable version) (PDF 126 KB)

    Published:
    29 May 2025

Invitation to participate

  • Final stakeholder list (PDF 189 KB)

    Published:
    29 August 2024
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 313 KB)

    Published:
    29 August 2024
  • Equality impact assessment (scoping) (PDF 133 KB)

    Published:
    29 August 2024
  • Final scope (PDF 193 KB)

    Published:
    29 August 2024

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3981

  • Draft scope post referral (PDF 200 KB)

    Published:
    28 May 2024
  • Draft matrix post referral (PDF 189 KB)

    Published:
    28 May 2024
Back to top